01 Mar 2018 by admin in UncategorizedComments Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
21 Feb 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
07 Feb 2018 by admin in UncategorizedComments Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
30 Jan 2018 by admin in UncategorizedComments resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
25 Jan 2018 by admin in UncategorizedComments ARMO BioSciences Announces Pricing of Initial Public Offering
16 Jan 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
03 Jan 2018 by admin in UncategorizedComments Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda
02 Jan 2018 by admin in UncategorizedComments Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018
30 Nov 2017 by admin in UncategorizedComments resTORbio Raises $40 Million to Advance Selective TORC1 Inhibitors for Aging-Related Diseases and Conditions
11 Nov 2017 by admin in UncategorizedComments How Quan Plans To Deploy Its Inaugural $150m Healthcare Fund
